

# CITATION REPORT

List of articles citing

Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol

DOI: 10.1200/jco.2005.55.405

Journal of Clinical Oncology, 2005, 23, 5883-91.

**Source:** <https://exaly.com/paper-pdf/38976123/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
381	Optimal therapy for unresectable stage III non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5853-5	2.2	29
380	Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. <b>2005</b> , 50, S17-S24		14
379	Chemoradiotherapy for lung cancer. <b>2005</b> , 6, 2793-804		3
378	Taxanes in the treatment of non-small cell lung cancer. <b>2006</b> , 5, 181-91		5
377	The role of radiation therapy in thoracic tumors. <b>2006</b> , 20, 363-400		17
376	CBNPC stades IIIB. <b>2006</b> , 23, 54-60		
375	Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer. <b>2006</b> , 8, 122-9		1
374	Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. <b>2006</b> , 52, 67-74		25
373	Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?. <b>2006</b> , 53, 323-30		21
372	Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. <b>2006</b> , 54, 331-8		9
371	Lung cancer. <b>2006</b> , 1, 235-272		1
370	Radiotherapy in Lung Cancer. 120-135		
369	Current Update on the Management of Locally Advanced Non-small Cell Lung Cancer. <b>2006</b> , 5, 1		
368	Management of Unresected Stage III Non-small Cell Lung Cancer: A Systematic Review. <b>2006</b> , 1, 377-393		32
367	Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer. <b>2006</b> , 1, 810-815		28
366	Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer. <b>2006</b> , 1, 810-815		33
365	Management of Unresected Stage III Non-small Cell Lung Cancer: A Systematic Review. <b>2006</b> , 1, 377-393		48

364	Concurrent end-phase boost high-dose radiation therapy for non-small-cell lung cancer with or without cisplatin chemotherapy. <b>2006</b> , 50, 342-8		4
363	Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes. <b>2006</b> , 66, 1004-10		44
362	Nichtkleinzelliges Lungenkarzinom im Stadium III. <b>2006</b> , 12, 753-760		1
361	Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. <b>2006</b> , 58, 735-41		8
360	Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). <b>2006</b> , 8, 116-21		66
359	Recent Clinical Trials in Non-Small Cell Lung Cancer. <b>2006</b> , 2, 81-99		
358	Chemoradiation paradigm for the treatment of lung cancer. <b>2006</b> , 3, 188-99		28
357	Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art. <b>2006</b> , 17, 1743-7		17
356	High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. <b>2006</b> , 9, 245-53		18
355	Multimodality treatment in locally advanced non-small cell lung cancer. <b>2006</b> , 17 Suppl 2, ii32-33		2
354	Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art. <b>2006</b> , 2, 67-72		
353	Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4397-404	2.2	107
352	Combined modality therapy for stage III non-small cell lung cancer. <i>Oncologist</i> , <b>2006</b> , 11, 809-23	5.7	32
351	Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1698-704	2.2	366
350	Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. <b>2007</b> , 18 Suppl 9, ix150-5		12
349	Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). <b>2007</b> , 132, 266S-276S		119
348	130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. <b>2007</b> , 13, 1868-74		55
347	Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. <b>2007</b> , 13, 1552-61		316

346	Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review. <b>2007</b> , 3, 127-139		
345	Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4146-52	2.2	81
344	Application of radiotherapy and chemotherapy protocols to pre-clinical tumor models. <b>2007</b> , Chapter 14, Unit 14.7		4
343	Current treatment paradigms for locally advanced non-small cell lung cancer. <b>2007</b> , 2 Suppl 2, S77-85		33
342	Multidisciplinary Team Management of Lung Cancer. <b>2007</b> ,		
341	Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. <b>2007</b> , 2, 927-32		12
340	Sequencing chemotherapy, radiotherapy and surgery in combined modality treatment of stage III nonsmall cell lung cancer. <b>2007</b> , 13, 297-304		8
339	A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. <b>2007</b> , 18, 713-9		7
338	[Treatment of localised lung cancer]. <b>2007</b> , 55, 299-303		
337	[Chemoradiation for locally advanced non-small cell lung cancer]. <b>2007</b> , 11, 67-76		3
336	Lung cancer management in limited resource settings: guidelines for appropriate good care. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 82, 123-31	5.3	30
335	Microtubule Protocols. <i>Methods in Molecular Medicine</i> , <b>2007</b> ,		3
334	Articulation de la chimiothérapie avec la radiothérapie dans les stades localement avancés du CBNPC. <b>2007</b> , 24, 94-100		1
333	A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). <b>2007</b> , 56, 247-54		8
332	Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. <b>2007</b> , 58, 238-45		11
331	[Stage IIIA and IIIB non-small cell lung cancer: results of chemotherapy combined with radiation therapy and analysis of prognostic factors]. <b>2007</b> , 43, 358-65		5
330	Induction Therapy with Paclitaxel and Carboplatin Followed by Hyperfractionated Radiotherapy plus Weekly Concurrent Chemotherapy and Subsequent Consolidation Therapy in Unresectable Locallyadvanced Non-Small-Cell Lung Cancer. <b>2007</b> , 93, 133-137		1
329	Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study. <i>Cancer</i> , <b>2007</b> , 110, 606-13	6.4	10

328	Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. <b>2007</b> , 68, 779-85		18
327	Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer. <b>2007</b> , 2, 27		24
326	Prognostic factors in stage III non-small-cell lung cancer. <b>2007</b> , 8, 478-82		42
325	Carcinoma de pulmón no microcítico. Estadios IIIA y B. Resultados del tratamiento combinado (quimioterapia y radioterapia) y análisis de factores pronósticos. <b>2007</b> , 43, 358-365		2
324	Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. <i>Clinical Oncology</i> , <b>2008</b> , 20, 666-76	2.8	32
323	Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer. <b>2008</b> , 71, 187-91		28
322	Routine use of continuous, hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer: a five-center experience. <b>2008</b> , 72, 716-22		22
321	Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. <b>2008</b> , 9, 92-101		22
320	Chemoradiation for unresectable stage III non-small cell lung cancer. <b>2008</b> , 20, 204-9		15
319	Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 87, 17-23	5.3	111
318	BLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancer. <b>2008</b> , 2, 37-45		22
317	Definitive chemoradiotherapy for non-small cell lung cancer with N2 disease. <b>2008</b> , 18, 393-401		5
316	Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2457-63	2.2	145
315	Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5755-60	2.2	385
314	Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer. <b>2008</b> , 3, 617-22		37
313	Locally advanced non-small cell lung cancer: the past, present, and future. <b>2008</b> , 3, 917-28		53
312	Management of Locally Advanced Non-small Cell Lung Cancer. <b>2009</b> , 8, 1		
311	PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. <b>2009</b> , 10, 183-9		47

310	Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. <i>Cancer</i> , <b>2009</b> , 115, 4156-66	6.4	34
309	Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , <b>2009</b> , 14, 408-15	4.2	12
308	Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , <b>2009</b> , 14, 507-12	4.2	3
307	NSCLC in the elderly--the legacy of therapeutic neglect. <b>2009</b> , 10, 180-94		9
306	Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. <b>2009</b> , 63, 1091-6		13
305	Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. <b>2009</b> , 101, 225-31		43
304	The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer. <b>2009</b> , 73, 1383-90		44
303	[State of the art in chemoradiotherapy combinations and potential role in targeting therapy approaches in nonsmall cell lung cancer]. <b>2009</b> , 13, 114-22		1
302	Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: mid-term results and indicators for survival. <b>2009</b> , 87, 1676-83		25
301	A phase II study of carboplatin and paclitaxel with meloxicam. <b>2009</b> , 63, 72-6		15
300	Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer. <b>2009</b> , 63, 63-7		7
299	A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. <b>2009</b> , 64, 187-93		24
298	A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. <b>2009</b> , 65, 74-9		14
297	How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. <b>2009</b> , 65, 62-7		20
296	Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens. <b>2009</b> , 10, 124-9		6
295	Radiotherapy for locally advanced non-small cell lung cancer. <b>2009</b> , 45 Suppl 1, 113-25		7
294	Chemotherapy in stage III non-small cell lung cancer. <b>2009</b> , 45 Suppl 1, 126-36		1
293	Chemotherapy in the older patient with operable non-small cell lung cancer: neoadjuvant and adjuvant regimens. <b>2009</b> , 19, 377-89		3

292	Prise en charge des CBNPC de stade III : la radiochimiothérapie concomitante. <b>2009</b> , 1, 393-400	
291	Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer. <b>2009</b> , 4, 983-7	6
290	Principes et traitements par chimiothérapie et radiothérapie des cancers bronchiques non ^petites cellules. <b>2009</b> , 6, 1-9	5
289	High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. <b>2009</b> , 4, 845-52	46
288	A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). <b>2009</b> , 4, 722-7	16
287	Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. <b>2009</b> , 4, 1117-25	32
286	Chemoradiotherapy in locally advanced, unresectable non-small cell lung cancer. <b>2009</b> , 4, 110-21	3
285	The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC). <b>2010</b> , 11, 67-73	29
284	Non-small cell lung cancer. <b>2010</b> , 8, 740-801	457
283	Management of lung cancer in older adults. 110-123	
282	Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. <b>2010</b> , 27, 152-7	10
281	Combined modality therapy for stage III non-small-cell lung cancer. <b>2010</b> , 20, 186-91	20
280	Analysis of a novel protocol of combined induction chemotherapy and concurrent chemoradiation in unresected non-small-cell lung cancer: a ten-year experience with vinblastine, Cisplatin, and radiation therapy. <b>2010</b> , 11, 243-50	9
279	Clinical perspectives on dose escalation for non-small-cell lung cancer. <b>2010</b> , 11, 299-302	9
278	Chemo-radiotherapy for advanced non-small cell lung cancer: concurrent or sequential? It's no longer the question: a systematic review. <b>2010</b> , 127, 718-28	20
277	Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence. <i>Clinical Oncology</i> , <b>2010</b> , 22, 347-55	2.8 33
276	Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808. <b>2010</b> , 76, 802-8	7
275	Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol. <b>2010</b> , 76, 1376-81	10

274	A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer. <b>2010</b> , 5, 84		11
273	Risk Factors for Fatal Hemoptysis after Concurrent Chemoradiation Therapy in Patients with Non-Small Cell Lung Carcinoma. <b>2010</b> , 46, 19		7
272	Radiation pneumonitis following twice-daily radiotherapy with concurrent carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer. <b>2010</b> , 40, 464-9		5
271	Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3739-45	2.2	215
270	Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3299-306	2.2	187
269	Recent advances in combined modality therapy. <i>Oncologist</i> , <b>2010</b> , 15, 372-81	5.7	28
268	[Prevention, diagnosis, therapy, and follow-up of lung cancer]. <b>2010</b> , 64 Suppl 2, e1-164		85
267	Guidelines on the radical management of patients with lung cancer. <b>2010</b> , 65 Suppl 3, iii1-27		274
266	Radiochemotherapy for Non Small Cell Lung Cancer. <b>2010</b> , 5, 180-191		
265	Radiation-guided drug delivery to mouse models of lung cancer. <b>2010</b> , 16, 4968-77		30
264	Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 942-8	2.2	64
263	[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]. <b>2011</b> , 28, 51-7		6
262	Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer. <b>2011</b> , 74, 69-74		17
261	Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer. <b>2011</b> , 74, 248-52		5
260	[Targeted therapies and radiation therapy in non-small cell lung cancer]. <b>2011</b> , 15, 527-35		4
259	Concurrent high-dose radiotherapy with low-dose chemotherapy in patients with non-small cell lung cancer of the superior sulcus. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 101, 278-83	5.3	12
258	Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. <b>2011</b> , 81, 985-91		15
257	Radiotherapy and Third Generation Concurrent Chemotherapy Agents. <i>Medical Radiology</i> , <b>2011</b> , 291-312	2.2	



256	Clinical Research in Radiation Oncology of Lung Cancer: Why We Fail(ed)?. <i>Medical Radiology</i> , <b>2011</b> , 809-818	
255	Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer. <b>2011</b> , 1, 47	6
254	Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. <b>2011</b> , 6, 934-41	53
253	Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study. <b>2011</b> , 6, 351-7	21
252	Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. <b>2011</b> , 6, 553-8	3
251	Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer. <b>2011</b> , 6, 1857-64	26
250	Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. <b>2011</b> , 6, 1079-86	11
249	Lung cancer: New biological insights and recent therapeutic advances. <b>2011</b> , 61, 91-112	329
248	The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. <b>2011</b> , 12, 166-71	51
247	Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study. <b>2011</b> , 12, 286-92	5
246	Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer. <b>2011</b> , 68, 1497-505	4
245	Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions. <b>2011</b> , 13, 629-35	4
244	Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. <b>2011</b> , 6, 171-80	9
243	The optimal chemotherapy for stage III non-small cell lung cancer patients. <i>Current Oncology Reports</i> , <b>2011</b> , 13, 272-9	6.3 6
242	Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. <b>2011</b> , 6, 17	8
241	Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. <i>Cancer</i> , <b>2011</b> , 117, 2986-94	6.4 49
240	Rapid disease progression with delay in treatment of non-small-cell lung cancer. <b>2011</b> , 79, 466-72	58
239	Daily megavoltage computed tomography in lung cancer radiotherapy: correlation between volumetric changes and local outcome. <b>2011</b> , 80, 1338-42	16

238	Preclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancer. <b>2011</b> , 80, 1358-64		4
237	Radiation Therapy in the Management of Lung Cancer. <b>2011</b> , 7, 323-339		
236	RTOG 94-10: keenly awaited results validating the best therapeutic strategy for locally advanced non-small cell lung cancer. <b>2011</b> , 103, 1425-7		2
235	Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. <b>2011</b> , 103, 1452-60		807
234	A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. <b>2011</b> , 41, 25-31		6
233	Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2312-8	2.2	132
232	Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. <b>2011</b> , 34, 249-53		57
231	A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. <b>2011</b> , 22, 553-558		29
230	Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist?. <b>2011</b> , 8, 5-6		
229	Emerging developments of chemoradiotherapy in stage III NSCLC. <b>2012</b> , 9, 591-8		17
228	Induction chemotherapy inevitably leads to inferior outcome in combined modality treatment for unresectable stage III non-small cell lung cancer. <b>2012</b> , 7, 944-5		
227	A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer. <b>2012</b> , 82, 14-20		11
226	Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. <b>2012</b> , 82, 425-34		202
225	Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients. <b>2012</b> , 82, 1157-63		7
224	A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer. <b>2012</b> , 48, 672-7		5
223	Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. <b>2012</b> , 23, 1730-8		57
222	Treatment of lung cancer. <b>2012</b> , 50, 961-74		62
221	The effect of radiotherapy practice pattern on survival of patients with locally advanced non-small cell lung cancer. <i>Clinical Oncology</i> , <b>2012</b> , 24, e194	2.8	

220	Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. <b>2012</b> , 77, 89-96		58
219	Radio-chimiothérapie optimale : questions résolues et non-résolues en 2012. <b>2012</b> , 4, 506-514		
218	One size does not fit all lung cancer patients. <b>2012</b> , 7, 945		
217	A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer. <b>2012</b> , 13, 205-13		21
216	Strahlentherapie des lokal fortgeschrittenen Lungenkarzinoms. <b>2012</b> , 9, 28-34		1
215	The role of consolidation treatment in locally advanced unresectable NSCLC. <i>Current Oncology Reports</i> , <b>2013</b> , 15, 424-32	6.3	3
214	Multimodality approach to management of stage III non-small cell lung cancer. <b>2013</b> , 22, 319-28		8
213	Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601. <b>2013</b> , 81, 91-6		17
212	Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401. <b>2013</b> , 72, 1353-9		4
211	Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer. <b>2013</b> , 21, 785-91		12
210	New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1029-38	2.2	61
209	Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study. <b>2013</b> , 81, 84-90		22
208	A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. <b>2013</b> , 81, 416-421		15
207	The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. <b>2013</b> , 80, 298-305		23
206	Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. <b>2013</b> , 42, 1119-33		11
205	Concurrent chemoradiotherapy with tomotherapy in locally advanced Non-Small Cell Lung Cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. <i>BMC Cancer</i> , <b>2013</b> , 13, 513	4.8	13
204	Induction chemotherapy followed by weekly paclitaxel and carboplatin with concurrent radiotherapy in inoperable stage III non-small cell lung cancers: results of a phase II trial. <b>2013</b> , 12, 56-60		
203	Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. <b>2013</b> , 8, 1181-9		87

202	Evolution of modern-era radiotherapy strategies for unresectable advanced non-small-cell lung cancer. <b>2013</b> , 2, 213-225	1
201	Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations. <b>2013</b> , 3, 176	6
200	Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). <b>2013</b> , 19, 231-7	31
199	A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer. <b>2013</b> , 5, 159-68	4
198	Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience. <b>2013</b> , 30, 187-92	7
197	Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. <b>2013</b> , 2, 916-24	22
196	Outcomes of chemoradiation for patients with locally advanced non-small-cell lung cancer. <b>2013</b> , 43, 790-7	2
195	Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer. <b>2013</b> , 2, 75-85	
194	Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. <b>2013</b> , 8, 1308-16	21
193	Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. <b>2013</b> , 143, e314S-e340S	309
192	The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. <b>2014</b> , 60, 107-111	3
191	Current status of induction treatment for N2-Stage III non-small cell lung cancer. <b>2014</b> , 62, 651-9	10
190	Combinations of Radiation Therapy and Chemotherapy for Non-Small Cell and Small-Cell Lung Carcinoma. <b>2014</b> , 353-378	
189	Controversies in the management of stage III non-small-cell lung cancer. <b>2014</b> , 14, 333-47	11
188	Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer. <b>2014</b> , 41, 57-68	16
187	How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?. <b>2014</b> , 83, 117-25	32
186	Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer. <b>2014</b> , 83, 67-72	0
185	Recent clinical advances in lung cancer management. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 973-82	2.2 169

184	Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 112, 272-8	5.3	22
183	Lung Cancer in Older Adults. <b>2014</b> , 3, 166-174		
182	Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy. <b>2014</b> , 9, 172		24
181	Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. <b>2014</b> , 134, 297-301		10
180	The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. <b>2014</b> , 15, 365-71		9
179	Non-small cell lung cancer, version 1.2015. <b>2014</b> , 12, 1738-61		130
178	Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-Small Cell Lung Cancer. <b>2014</b> , 379-389		
177	Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. <b>2015</b> , 10, 1685-93		38
176	An update on current standards and clinical trials in systemic therapy for stage III NSCLC. <b>2015</b> , 4, 289-297		
175	Cancer bronchique non ^petites cellules localement avanc: quand et comment intgrer chimiothrapie et radiothrapie ?. <b>2015</b> , 7, 387-397		
174	Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. <b>2015</b> , 87, 232-40		17
173	Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer. <i>BMC Cancer</i> , <b>2015</b> , 15, 36	4.8	7
172	Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. <b>2015</b> , 92, 627-33		34
171	Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. <i>Practical Radiation Oncology</i> , <b>2015</b> , 5, 141-148	2.8	60
170	Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: challenges in the selection of appropriate chemotherapy. <b>2015</b> , 25, 122-32		7
169	Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression. <b>2015</b> , 14, 1693-704		18
168	ACR Appropriateness Criteria( ) induction and adjuvant therapy for N2 non-small-cell lung cancer. <b>2015</b> , 38, 197-205		7
167	Optimal Concurrent Chemoradiotherapy Regimen in Non-Small-Cell Lung Cancer: Prospective, Randomized Data Still Required. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2928	2.2	3

166	Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration. <b>2015</b> , 16, 47			6
165	Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer. <b>2015</b> , 93, 997-1004			9
164	Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 567-74	2.2		88
163	Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer. <b>2015</b> , 87, 23-7			18
162	Lung cancer in Brazil: epidemiology and treatment challenges. <b>2016</b> , 7, 141-148			10
161	Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer. <b>2016</b> , 9, 921-8			6
160	Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 190-4	4.4		
159	Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer. <b>2016</b> , 6, 260			6
158	Involved-field Radiation Therapy for Patients with Stage III Non-small-cell Lung Cancer: Early Results of Hypofractionated Involved-field Radiation Therapy. <i>Japanese Journal of Lung Cancer</i> , <b>2016</b> , 56, 1003-1011	0.1		1
157	Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy. <b>2016</b> , 39, 355-62			8
156	Radiothérapie et traitements combinés des cancers bronchiques non ^ petites cellules localement avancés. <b>2016</b> , 18, 385-391			1
155	LZ-106, a novel analog of enoxacin, inducing apoptosis via activation of ROS-dependent DNA damage response in NSCLCs. <b>2016</b> , 95, 155-68			24
154	Overview. <b>2016</b> , 788-797.e4			
153	Sulforaphene-Carboplatin Combination Synergistically Enhances Apoptosis by Disruption of Mitochondrial Membrane Potential and Cell Cycle Arrest in Human Non-Small Cell Lung Carcinoma. <b>2016</b> , 19, 860-9			18
152	Treatment: Radiation Therapy. <i>Cancer Treatment and Research</i> , <b>2016</b> , 170, 105-18	3.5		12
151	Multimodality Therapy for NSCLC. <i>Cancer Treatment and Research</i> , <b>2016</b> , 170, 151-63	3.5		5
150	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <b>2016</b> , 100, 30-37			3
149	Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4280	1.8		9

148	Chemotherapy in non-small cell lung cancer: opportunities for advancement. <b>2016</b> , 35, 56		4
147	[Progression-free survival of patients with locally advanced NSCLC not improved by consolidation chemotherapy after concurrent chemoradiation]. <b>2016</b> , 192, 133-5		
146	Kein Vorteil für das PFS bei Patienten mit lokal fortgeschrittenem NSCLC. <b>2016</b> , 19, 12-14		
145	Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. <b>2016</b> , 98, 106-113		33
144	Interaction of Chemotherapy and Radiation. <b>2016</b> , 63-79.e4		3
143	Neoadjuvant Therapy in Non-Small Cell Lung Cancer. <b>2016</b> , 25, 567-84		14
142	Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy. <b>2016</b> , 10, 428-34		1
141	What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review. <b>2016</b> , 34, 80-93		8
140	Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 767	2.2	3
139	Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer. <b>2016</b> , 17, 133-41		5
138	Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer. <b>2016</b> , 15, 842-53		11
137	Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. <b>2016</b> , 37, 8901-7		9
136	Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01. <b>2016</b> , 52, 181-7		15
135	Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer. <b>2016</b> , 94, 147-154		31
134	Management of Lung Cancer in the Elderly. <b>2016</b> , 32, 81-95		12
133	Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. <b>2017</b> , 79, 381-387		5
132	Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer. <b>2017</b> , 18, 565-571		5
131	Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study. <b>2017</b> , 13, 137-144		2



130	The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis. <i>Medicine (United States)</i> , <b>2017</b> , 96, e6165	1.8	10
129	Cancer of the Lung. <b>2017</b> , 1-30		0
128	Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non-Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older. <b>2017</b> , 18, 460-471		20
127	Treatment of Locally Advanced Non-Small Cell Lung Cancer. <b>2017</b> , 31, 45-57		6
126	A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. <b>2017</b> , 108, 173-182		8
125	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). <b>2017</b> , 18, 333-339		32
124	Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6-10	2.2	30
123	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. <b>2017</b> , 17, 157-165		
122	Case series of multiple primary cancers in single individuals: diagnostic and therapeutic dilemmas. <b>2017</b> , 7, 238-240		1
121	Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer. <b>2017</b> , 99, 652-659		15
120	Management of stage III non-small cell lung cancer. <b>2017</b> , 44, 163-177		27
119	Radiogenomics and radiotherapy response modeling. <b>2017</b> , 62, R179-R206		33
118	National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. <b>2017</b> , 97, 128-137		80
117	Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value. <b>2017</b> , 3, 285-288		6
116	Quelle est la meilleure squence thrapeutique pour les CBNPC non-opfables ?. <b>2017</b> , 9, 190-201		
115	The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer. <b>2017</b> , 7, 201		3
114	Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"?. <b>2017</b> , 7, 205		6
113	Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients. <b>2017</b> , 12, 165		2



112	Therapeutic management options for stage III non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , <b>2017</b> , 8, 1-20	2.5	127
111	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. <b>2018</b> , 66, 114-121		25
110	A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. <b>2018</b> , 117, 32-37		8
109	Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis. <b>2018</b> , 100, 748-755		16
108	Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. <b>2018</b> , 41, 362-366		11
107	Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy. <b>2018</b> , 100, 452-461		11
106	Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer. <b>2018</b> , 14, 91-100		5
105	Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, S2465-S2473	2.6	24
104	Curative Intent Treatment of Stage III Non-Small Cell Lung Cancer. <b>2018</b> , 83-98		
103	Phase I Study of Concurrent and Consolidation Cisplatin and Docetaxel Chemotherapy with Thoracic Radiotherapy in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , <b>2018</b> , 25, 22-31	2.8	
102	Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer. <b>2018</b> , 125, 136-141		9
101	PACIFIC: An Ocean of Hope in Patients With Stage III Unresectable Non-Small Cell Lung Cancer. <b>2018</b> , 16, 458-460		
100	Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. <b>2018</b> , 19, 39		9
99	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 931-940	3.6	8
98	Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer. <b>2018</b> , 8, 5		21
97	Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. <b>2019</b> , 14, 112		7
96	The Role of Additional Chemotherapy in Combination with Concurrent Chemoradiotherapy for Locally Advanced Inoperable Non-Small Cell Lung Cancer, a Systematic Review and Meta-Analysis of 12 Randomized Trials. <b>2019</b> , 37, 376-386		1
95	Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes. <b>2019</b> , 36, 563-578		6

94	Absolute Clinical Radiation Oncology Review. <b>2019</b> ,		2
93	Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer. <i>Medicine (United States)</i> , <b>2019</b> , 98, e14463	1.8	18
92	Management of Locally Advanced Lung Cancer. <b>2019</b> , 57-86		1
91	A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer. <i>Cancer</i> , <b>2019</b> , 125, 2148-2153	6.4	0
90	Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. <b>2019</b> , 46, 1439-1447		1
89	Radiotherapy for patients with completely resected pathologic IIIA(N2) non-small-cell lung cancer: a retrospective analysis. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 10901-10908	3.6	2
88	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. <b>2019</b> , 28,		22
87	Cancers bronchiques localement avancés ou inopérables: rôle de l'oncologue. <b>2019</b> , 11, 265-277		
86	Cancer of the Lung: Non-small Cell Lung Cancer and Small Cell Lung Cancer. <b>2020</b> , 1108-1158.e16		5
85	Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 475-e891	5.7	4
84	Radiation Therapy for Thoracic Malignancies. <b>2020</b> , 34, 109-125		4
83	Cancers bronchiques localement avancés ou inopérables stades III : le rôle du pneumo-oncologue. <b>2020</b> , 12, 2S117-2S131		
82	The changing landscape of stage III lung cancer: a literature review. <b>2020</b> , 20, 675-686		1
81	A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. <i>Cancer</i> , <b>2020</b> , 126, 4353-4361	6.4	41
80	Pulmonary toxicity of systemic lung cancer therapy. <i>Respirology</i> , <b>2020</b> , 25 Suppl 2, 72-79	3.6	8
79	Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , <b>2020</b> , 25, 2015-2024	4.2	0
78	Risk Stratification of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Chemo-Radiotherapy: An Institutional Analysis. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 7165-7171	3.6	1
77	Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)-a German radiation oncology survey. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 288-293	4.4	4

76	Locally Advanced, Unresectable Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , <b>2020</b> , 22, 31	6.3	7
75	Management guidelines for stage III non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 157, 103144	7	5
74	Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , <b>2021</b> , 26, 19-e52	5.7	1
73	Phase II Study: The Outcome of Hypofractionated Involved-Field Radiation Therapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Non-small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , <b>2021</b> , 11, 35-43	2.8	2
72	The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. <i>Pulmonology</i> , <b>2021</b> , 27, 26-34	3.7	4
71	Patterns of Care and Barriers to Utilization of Definitive Concurrent Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer in Russia. <i>Journal of Cancer Education</i> , <b>2021</b> , 1	1.8	
70	A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer. <i>Scientific Reports</i> , <b>2021</b> , 11, 5939	4.9	3
69	Concurrent vs sequential chemoradiotherapy for patients with advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. <i>Medicine (United States)</i> , <b>2021</b> , 100, e21455	1.8	1
68	AN OBSERVATIONAL STUDY TO EVALUATE THE RESPONSE AND TOXICITY WITH CONVENTIONAL FRACTIONATION AND HYPO FRACTIONATED RADIOTHERAPY FOR LOCALLY ADVANCED NON SMALL CELL LUNG CARCINOMA FOLLOWING INDUCTION CHEMOTHERAPY. <b>2021</b> , 7-9		
67	Impact of Chronic Obstruction Pulmonary Disease on Survival in Patients with Advanced Stage Lung Squamous Cell Carcinoma Undergoing Concurrent Chemoradiotherapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
66	Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB/IIIA Non-small Cell Lung Cancer - A Phase II trial. <i>Clinical Oncology</i> , <b>2021</b> , 33, e553-e560	2.8	0
65	Lung Neoplasms. <b>2008</b> , 1491-1523		2
64	Clinical pharmacology and use of microtubule-targeting agents in cancer therapy. <i>Methods in Molecular Medicine</i> , <b>2007</b> , 137, 209-34		11
63	Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. <b>2008</b> , 1307-1366		4
62	Interaction of Chemotherapy and Radiation. <b>2012</b> , 65-82		9
61	Cancer of the Lung. <b>2014</b> , 1143-1192.e13		3
60	Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience. <i>Medical Science Monitor</i> , <b>2015</b> , 21, 661-6	3.2	6
59	Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157455	3.7	7

58	The role of chemotherapy in the management of stage IIIA non-small cell lung cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , 320-5	7.1	3
57	Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study. <i>Oncotarget</i> , <b>2017</b> , 8, 49084-49092	3.3	7
56	Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 15690-703	3.3	23
55	Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes. <i>Oncotarget</i> , <b>2016</b> , 7, 18135-45	3.3	17
54	Automated Information Extraction on Treatment and Prognosis for Non-Small Cell Lung Cancer Radiotherapy Patients: Clinical Study. <i>JMIR Medical Informatics</i> , <b>2018</b> , 6, e8	3.6	5
53	A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer. <i>Radiology and Oncology</i> , <b>2019</b> , 53, 6-14	3.8	16
52	Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. <i>Health Technology Assessment</i> , <b>2013</b> , 17, 1-99	4.4	40
51	Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. <i>Journal of Thoracic Disease</i> , <b>2011</b> , 3, 197-204	2.6	38
50	Radiation dose effect in locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , <b>2014</b> , 6, 336-47	2.6	29
49	Saudi lung cancer management guidelines 2017. <i>Annals of Thoracic Medicine</i> , <b>2017</b> , 12, 221-246	2.2	9
48	Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2012</b> , 44, 74-84	5.2	9
47	Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status. <i>Cancer Research and Treatment</i> , <b>2017</b> , 49, 981-989	5.2	10
46	Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , <b>2015</b> , 6, 156-65	2.5	7
45	Staging with PET-CT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2013</b> , 14, 3743-6	1.7	15
44	Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2014</b> , 15, 2465-72	1.7	14
43	Synthesis of Doxorubicin-Loaded Nanobubble and Its Effect on Targeted Therapy for Patients with Ovarian Cancer. <i>Science of Advanced Materials</i> , <b>2021</b> , 13, 1114-1124	2.3	0
42	Treatment of non-small cell lung cancer. <b>2006</b> , 127-196		
41	Weekly Paclitaxel and Carboplatin with Concurrent Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , <b>2007</b> , 47, 855-859	0.1	

40	Advances in Chemoradiation Treatment of Locoregionally Advanced NonSmall Cell Lung Cancer. <i>Translational Medicine Series</i> , <b>2007</b> , 175-206		
39	Guidelines and Techniques for Image-Guided Radiotherapy for NonSmall Cell Lung Cancer. <b>2007</b> , 19-37		
38	Image Guidance of Screening, Staging and Combined Modality Management of NonSmall Cell Lung Cancer. <b>2007</b> , 1-17		
37	Combined Chemoradiotherapy Advances. <i>Cancer Treatment and Research</i> , <b>2008</b> , 277-301	3.5	1
36	Advances in the Treatment of Lung Cancer. <b>2009</b> , 545-552		
35	Non-small Cell Lung Cancer. <b>2010</b> , 221-247		2
34	Overview. <b>2012</b> , 783-793		
33	NonSmall Cell Lung Cancer. <b>2013</b> , 45-62		
32	The treatment strategy for clinical stage III non-small cell lung cancer. <i>Okayama Igakkai Zasshi</i> , <b>2013</b> , 125, 119-127		0
31	Advances in Radiotherapy for Locally Advanced NSCLC. <b>2015</b> , 69-94		
30	Three-dimensional Conformal Radiotherapy and Dose-fractionation for Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , <b>2015</b> , 55, 913-917	0.1	1
29	Advances in radiotherapy for lung cancer. <i>Onkologie (Czech Republic)</i> , <b>2018</b> , 12, 155-160	0.1	2
28	Lung Cancer. <b>2019</b> , 197-232		
27	Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a retrospective study. <i>Ortadoġ Tġ Dergisi</i> , <b>2019</b> , 11, 40-46	0.1	
26	Chemotherapy of Non-Small Cell Lung Cancer: Most Frequent Complications of Treatment and Methods of Dealing with them. <i>Medical Alphabet</i> , <b>2019</b> , 2, 43-48	0.3	
25	A randomized prospective study comparing concomitant chemoradiotherapy using paclitaxel-carboplatin with concomitant chemoradiotherapy using etoposide-cisplatin in inoperable or nonresectable locally advanced non-small cell lung cancer. <i>Clinical Cancer Investigation Journal</i> , <b>2020</b> , 9, 27	0.2	
24	State of the art of radiotherapy. <i>Translational Lung Cancer Research</i> , <b>2013</b> , 2, 189-99	4.4	1
23	Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer. <i>Current Oncology</i> , <b>2018</b> , 25, 22-31	2.8	

22	[Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel ?Administrated Every Three Weeks in Inoperable Advanced ?Non-small Cell Lung Cancer: ?A Retrospective Study from A Single Center]. <i>Chinese Journal of Lung Cancer</i> , <b>2016</b> , 19, 731-737	0.6	1
21	[Research progresses of albumin-bound paclitaxel in the treatment of non-small cell lung cancer]. <i>Chinese Journal of Lung Cancer</i> , <b>2010</b> , 13, 748-52	0.6	
20	Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP model. <i>Radiotherapy and Oncology</i> , <b>2021</b> ,	5.3	0
19	Radiation Oncology of Lung Cancer: Why We Fail(ed) in Clinical Research?. <i>Medical Radiology</i> , <b>2021</b> ,	0.2	
18	Combined Radiation Therapy and Chemotherapy as an Exclusive Treatment Option in Locally Advanced Inoperable Non-small Cell Lung Cancer. <i>Medical Radiology</i> , <b>2021</b> ,	0.2	1
17	Radiomic Phenotypes for Improving Early Prediction of Survival in Stage III Non-Small Cell Lung Cancer Adenocarcinoma after Chemoradiation.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
16	Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101707	2.2	1
15	CLINICAL OUTCOME USING WEEKLY PACLITAXEL WITH RADIATION IN LOCALLY ADVANCED LUNG CANCER. <b>2022</b> , 23-25		
14	Association of Diabetes Severity and Mortality with Lung Squamous Cell Carcinoma. <i>Cancers</i> , <b>2022</b> , 14, 2553	6.6	1
13	Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review. <i>Cancers</i> , <b>2022</b> , 14, 2680	6.6	1
12	A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer. <i>BMC Cancer</i> , <b>2022</b> , 22,	4.8	1
11	Clinical Effects of PET-CT Before Definite Concurrent Chemoradiotherapy in Patients With Unresectable Stage IIIA-III B Squamous Cell Carcinoma of the Lungs. <i>Clinical Nuclear Medicine</i> , Publish Ahead of Print,	1.7	
10	Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies. <b>2022</b> , 90, 229-237		
9	Chemotherapy for Lung Cancer. <b>2022</b> ,		0
8	Cancers bronchiques de stade III : rle de la radiothfapie. <b>2022</b> , 14, 2S106-2S112		0
7	Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung CancerHow to Identify Patients Which Can Benefit from It?. <b>2022</b> , 29, 8316-8329		0
6	A Comprehensive Survey on the Progress, Process, and Challenges of Lung Cancer Detection and Classification. <b>2022</b> , 2022, 1-43		0
5	VATS versus Open Lobectomy Following Induction Therapy for Stage III NSCLC: A Propensity Score-Matched Analysis. <b>2023</b> , 15, 414		0

- 4 Treatment patterns and long-term survival outcomes for patients with stage III non-small cell lung cancer: A retrospective study. ○
- 3 Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer. 13, ○
- 2 Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer. **2023**, 17, 117955492311529 ○
- 1 Locally Advanced Lung Cancer. **2023**, ○